Announcement • May 12
Novanta Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2026 Novanta Inc. provided earnings guidance for the second quarter and full year of 2026. For the quarter, the company expects GAAP revenue to be in the range of $259 million to $264 million.
For the year, the company expects GAAP revenue to be in the range of $1,040 million to $1,055 million. Announcement • Apr 14
Novanta Inc. to Report Q1, 2026 Results on May 11, 2026 Novanta Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 11, 2026 Announcement • Feb 24
Novanta Inc. Provides Revenue Guidance for the First Quarter and for the Full Year 2026 Novanta Inc. provided revenue guidance for the first quarter and For the full year 2026. For the first quarter of 2026, the Company expects GAAP revenue to be in the range of $250 million to $255 million.
For the full year, the Company expects GAAP revenue to be in the range of $1,030 million to $1,050 million. Announcement • Feb 10
Novanta Inc., Annual General Meeting, May 28, 2026 Novanta Inc., Annual General Meeting, May 28, 2026. Announcement • Jan 22
Novanta Inc. to Report Q4, 2025 Results on Feb 24, 2026 Novanta Inc. announced that they will report Q4, 2025 results Pre-Market on Feb 24, 2026 Announcement • Nov 07
Novanta Inc. has completed a Composite Units Offering in the amount of $550 million. Novanta Inc. has completed a Composite Units Offering in the amount of $550 million.
Security Name: Units
Security Type: Debt/Equity Composite Units
Securities Offered: 11,000,000
Price\Range: $50
Discount Per Security: $1.375 Announcement • Nov 04
Novanta Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2025 and Fiscal Year 2026 Novanta Inc. provided earnings guidance for the fourth quarter and full year of 2025 and fiscal year 2026. For the fourth quarter of 2025, the Company expects GAAP revenue of approximately $253 million to $257 million.
For the full year 2025, the Company expects GAAP revenue of approximately $975 million to $979 million.
Looking forward to full year 2026, the company now expects to deliver mid-single digit organic revenue growth as a result of continued momentum in business and end markets, the strength of new design wins, and new product launches. Announcement • Oct 08
Novanta Inc. to Report Q3, 2025 Results on Nov 04, 2025 Novanta Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 04, 2025 Announcement • Sep 19
Novanta Inc. Announces the Resignation of Barbara Hulit as Member of the Board of Directors and the Audit Committee and Environmental, Social and Governance Committee of the Board, Effective November 1, 2025 Novanta Inc. announced that on September 15, 2025, Barbara Hulit resigned as a member of the Board of Directors of the company and the Audit Committee and Environmental, Social and Governance Committee of the Board, effective November 1, 2025. Ms. Hulit’s decision to resign was not because of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Announcement • Aug 05
Novanta Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2025 Novanta Inc. provided earnings guidance for the third quarter and full year 2025. For the quarter, the Company expects GAAP revenue of approximately $244 million to $247 million.
For the full year 2025, the Company expects GAAP revenue of approximately $970 million to $985 million. Announcement • Jul 13
Novanta Inc. Announces Departure of Michele D. Welsh, General Counsel and Corporate Secretary, Effective on July 18, 2025 On July 8, 2025, Novanta Inc. (the Company) announced that Michele D. Welsh, General Counsel and Corporate Secretary of the Company, would no longer serve in those positions, effective on July 18, 2025, or such earlier date as may be agreed between Ms. Welsh and the Company. There are no changes to the severance that Ms. Welsh is entitled to receive pursuant to Section 4(a)(iv) of Ms. Welsh’s employment agreement dated July 11, 2022. Announcement • Jul 09
Novanta Inc. to Report Q2, 2025 Results on Aug 05, 2025 Novanta Inc. announced that they will report Q2, 2025 results on Aug 05, 2025 Announcement • May 07
Novanta Inc. (NasdaqGS:NOVT) acquired Keonn Technologies, S.L. for €60.6 million. Novanta Inc. (NasdaqGS:NOVT) acquired Keonn Technologies, S.L. for €60.6 million on April 8, 2025. A an initial cash payment of €60.6 million ($66.4 million), subject to customary closing and net working capital adjustments. The purchase includes up to €20.0 million ($21.9 million) in contingent consideration payable upon the achievement of certain revenue targets through December 2027. In addition, the Company has granted equity totaling €9.0 million ($9.9 million) to Keonn employees. The Keonn acquisition will be included in the Medical Solutions reportable segment. On April 8, 2025, Novanta drew down on revolving credit facility under the Senior Credit Facilities to fund the acquisition of Keonn Technologies, S.L. The acquisition was financed with cash on-hand and borrowings under Novanta's revolving credit facility.
Novanta Inc. (NasdaqGS:NOVT) completed the acquisition of Keonn Technologies, S.L. on April 8, 2025. Announcement • May 06
Novanta Inc. Provides Earnings Guidance for the Second Quarter of 2025 Novanta Inc. provided earnings guidance for the second quarter of 2025. For the quarter, the Company expects GAAP revenue of approximately $230 million to $240 million. Announcement • Apr 28
Novanta Inc., Annual General Meeting, May 29, 2025 Novanta Inc., Annual General Meeting, May 29, 2025. Announcement • Apr 09
Novanta Inc. to Report Q1, 2025 Results on May 06, 2025 Novanta Inc. announced that they will report Q1, 2025 results on May 06, 2025 Announcement • Feb 26
Novanta Inc. Provides Earnings Guidance for the First Quarter of 2025 and Full Year 2025 Novanta Inc. provided earnings guidance for the first quarter of 2025 and full year 2025. For the quarter, the company expects GAAP revenue of approximately $232 million to $236 million.
For the year, the company expects GAAP revenue of approximately $1.0 billion, representing revenue growth of approximately 5% year-over-year. Announcement • Jan 29
Novanta Inc. to Report Q4, 2024 Results on Feb 25, 2025 Novanta Inc. announced that they will report Q4, 2024 results on Feb 25, 2025 Recent Insider Transactions • Nov 14
CEO & Chairman of the Board recently sold €1.3m worth of stock On the 11th of November, Matthijs Glastra sold around 8k shares on-market at roughly €169 per share. This transaction amounted to 5.6% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Matthijs' only on-market trade for the last 12 months. Reported Earnings • Nov 08
Third quarter 2024 earnings released: EPS: US$0.53 (vs US$0.59 in 3Q 2023) Third quarter 2024 results: EPS: US$0.53 (down from US$0.59 in 3Q 2023). Revenue: US$244.4m (up 10% from 3Q 2023). Net income: US$19.2m (down 9.6% from 3Q 2023). Profit margin: 7.9% (down from 9.6% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Electronic industry in Germany. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 5% per year. Announcement • Nov 05
Novanta Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2024 and Revenue Guidance for the Year 2025 Novanta Inc. provided earnings guidance for the fourth quarter and full year of 2024 and revenue guidance for the year 2025. For the fourth quarter of 2024, the company expects GAAP revenue of approximately $237 million to $242 million.
For the full year 2024, the company expects GAAP revenue of approximately $948 million to $953 million.
The company expects organic revenue growth of up to 10% in 2025 compared to 2024. Announcement • Oct 09
Novanta Inc. to Report Q3, 2024 Results on Nov 05, 2024 Novanta Inc. announced that they will report Q3, 2024 results on Nov 05, 2024 Announcement • Aug 24
Novanta Inc. Announces Executive Changes On August 22, 2024, John Burke, formerly Vice President of Global Accounting for Novanta Inc. (company) was appointed Chief Accounting Officer of the company and assumed the role of principal accounting officer. Mr. Burke succeeds Peter Chang, Chief Accounting Officer and Corporate Controller of the Company, who departed from the role effective August 22, 2024. Mr. Chang, who served thirteen years in the role, will serve as an advisor to the Chief Financial Officer until his anticipated departure from the Company on February 28, 2025, and will assist with the transition of the Chief Accounting Officer role. Mr. Burke, age 43, has been it’s Vice President of Global Accounting since 2021, and previously served as Vice President of Accounting from 2017 to 2021 and Assistant Corporate Controller from 2011 to 2017. Prior to joining the company, Mr. Burke worked as the Manager of Technical Accounting and Reporting at MilliporeSigma (formerly known as Millipore Corporation), and prior to that, as an audit manager in the Boston office of PricewaterhouseCoopers LLP. Mr. Burke is a Certified Public Accountant and has a Bachelor of Business Administration degree in Accounting from the University of Massachusetts-Amherst. Reported Earnings • Aug 07
Second quarter 2024 earnings released: EPS: US$0.38 (vs US$0.58 in 2Q 2023) Second quarter 2024 results: EPS: US$0.38 (down from US$0.58 in 2Q 2023). Revenue: US$235.9m (up 2.8% from 2Q 2023). Net income: US$13.8m (down 34% from 2Q 2023). Profit margin: 5.8% (down from 9.1% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Electronic industry in Germany. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Announcement • Aug 07
Novanta Inc. Provides Earnings Guidance for the Third Quarter and Full Year of 2024 Novanta Inc. provided earnings guidance for the third quarter and full year of 2024. For the quarter, Company expects GAAP revenue of approximately $241 millionto $244 million.
For the year, the company expects GAAP revenue of approximately $975 million, representing reported revenue growth of greater than 10%. Announcement • Jul 10
Novanta Inc. to Report Q2, 2024 Results on Aug 06, 2024 Novanta Inc. announced that they will report Q2, 2024 results on Aug 06, 2024 Announcement • May 08
Novanta Inc. Provides Earnings Guidance for the Second Quarter of 2024 Novanta Inc. provided earnings guidance for the second quarter of 2024. For the quarter, the Company expects GAAP revenue of approximately $230 million to $235 million. Reported Earnings • May 07
First quarter 2024 earnings released: EPS: US$0.41 (vs US$0.51 in 1Q 2023) First quarter 2024 results: EPS: US$0.41 (down from US$0.51 in 1Q 2023). Revenue: US$230.9m (up 5.4% from 1Q 2023). Net income: US$14.7m (down 20% from 1Q 2023). Profit margin: 6.4% (down from 8.3% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Electronic industry in Germany. Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 13% per year. Announcement • Apr 10
Novanta Inc. to Report Q1, 2024 Results on May 07, 2024 Novanta Inc. announced that they will report Q1, 2024 results at 12:30 PM, US Eastern Standard Time on May 07, 2024 Announcement • Mar 01
Novanta Inc., Annual General Meeting, May 08, 2024 Novanta Inc., Annual General Meeting, May 08, 2024. Announcement • Feb 29
Novanta Inc. Provides Revenue Guidance for the First Quarter and Full Year of 2024 Novanta Inc. provided revenue guidance for the first quarter and full year of 2024. For the quarter, company expects GAAP revenue of approximately $225 million to $230 million. For the year, Company expects GAAP revenue of approximately $975 million to $1 billion. Reported Earnings • Feb 29
Full year 2023 earnings released: EPS: US$2.03 (vs US$2.08 in FY 2022) Full year 2023 results: EPS: US$2.03 (down from US$2.08 in FY 2022). Revenue: US$881.7m (up 2.4% from FY 2022). Net income: US$72.9m (down 1.6% from FY 2022). Profit margin: 8.3% (down from 8.6% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.3% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Electronic industry in Germany. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Announcement • Jan 30
Novanta Inc. to Report Q4, 2023 Results on Feb 28, 2024 Novanta Inc. announced that they will report Q4, 2023 results on Feb 28, 2024 Valuation Update With 7 Day Price Move • Nov 17
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €132, the stock trades at a forward P/E ratio of 63x. Average forward P/E is 11x in the Electronic industry in Germany. Total returns to shareholders of 38% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €86.58 per share. Announcement • Nov 09
Novanta Inc. Provides Revenue Guidance for the Fourth Quarter of 2023 and Full Year 2023 Novanta Inc. provides revenue guidance for the fourth quarter of 2023 and full year 2023. For the fourth quarter of 2023, the Company expects GAAP revenue of approximately $208 million to $212 million. For the full year 2023, the Company expects GAAP revenue of approximately $878 million to $882 million. Reported Earnings • Nov 08
Third quarter 2023 earnings released: EPS: US$0.59 (vs US$0.63 in 3Q 2022) Third quarter 2023 results: EPS: US$0.59 (down from US$0.63 in 3Q 2022). Revenue: US$221.5m (flat on 3Q 2022). Net income: US$21.2m (down 5.6% from 3Q 2022). Profit margin: 9.6% (in line with 3Q 2022). Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Electronic industry in Germany. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Announcement • Oct 11
Novanta Inc. to Report Q3, 2023 Results on Nov 07, 2023 Novanta Inc. announced that they will report Q3, 2023 results on Nov 07, 2023 Reported Earnings • Aug 09
Second quarter 2023 earnings released: EPS: US$0.58 (vs US$0.49 in 2Q 2022) Second quarter 2023 results: EPS: US$0.58 (up from US$0.49 in 2Q 2022). Revenue: US$229.5m (up 6.6% from 2Q 2022). Net income: US$20.9m (up 20% from 2Q 2022). Profit margin: 9.1% (up from 8.1% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.6% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Electronic industry in Germany. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 09
Second quarter 2023 earnings released: EPS: US$0.58 (vs US$0.49 in 2Q 2022) Second quarter 2023 results: EPS: US$0.58 (up from US$0.49 in 2Q 2022). Revenue: US$229.5m (up 6.6% from 2Q 2022). Net income: US$20.9m (up 20% from 2Q 2022). Profit margin: 9.1% (up from 8.1% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.6% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Electronic industry in Germany. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth. Announcement • Aug 09
Novanta Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2023 Novanta Inc. provided earnings guidance for the third quarter and full year 2023. For the quarter, the Company expects GAAP revenue of approximately $221 million to $224 million.For the full year 2023, the Company expects GAAP revenue of approximately $892 million to $902 million. Announcement • Jul 12
Novanta Inc. to Report Q2, 2023 Results on Aug 08, 2023 Novanta Inc. announced that they will report Q2, 2023 results at 9:30 AM, US Eastern Standard Time on Aug 08, 2023 Announcement • May 10
Novanta Inc. Provides Earnings Guidance for the Second Quarter of 2023 Novanta Inc. provided earnings guidance for the second quarter of 2023. For the quarter, the company expects GAAP revenue of approximately $222 million to $225 million. Reported Earnings • May 10
First quarter 2023 earnings released: EPS: US$0.51 (vs US$0.53 in 1Q 2022) First quarter 2023 results: EPS: US$0.51 (down from US$0.53 in 1Q 2022). Revenue: US$219.1m (up 7.3% from 1Q 2022). Net income: US$18.3m (down 2.9% from 1Q 2022). Profit margin: 8.3% (down from 9.2% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.9% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Electronic industry in Germany. Over the last 3 years on average, earnings per share has increased by 23% per year whereas the company’s share price has increased by 22% per year. Reported Earnings • Mar 02
Full year 2022 earnings released: EPS: US$2.08 (vs US$1.42 in FY 2021) Full year 2022 results: EPS: US$2.08 (up from US$1.42 in FY 2021). Revenue: US$860.9m (up 22% from FY 2021). Net income: US$74.1m (up 47% from FY 2021). Profit margin: 8.6% (up from 7.1% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.3% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Electronic industry in Germany. Over the last 3 years on average, earnings per share has increased by 22% per year whereas the company’s share price has increased by 18% per year. Announcement • Feb 02
Novanta Inc. to Report Q4, 2022 Results on Mar 01, 2023 Novanta Inc. announced that they will report Q4, 2022 results on Mar 01, 2023 Board Change • Nov 16
High number of new directors There are 6 new directors who have joined the board in the last 3 years. Director Barbara Hulit was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 09
Third quarter 2022 earnings released: EPS: US$0.63 (vs US$0.38 in 3Q 2021) Third quarter 2022 results: EPS: US$0.63 (up from US$0.38 in 3Q 2021). Revenue: US$223.0m (up 26% from 3Q 2021). Net income: US$22.5m (up 65% from 3Q 2021). Profit margin: 10% (up from 7.7% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Electronic industry in Germany. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Nov 09
Novanta Inc. Provides Financial Guidance for the Fourth Quarter and Full Year 2022 Novanta Inc. provided financial guidance for the fourth quarter and full year 2022. For the fourth quarter of 2022, the Company expects GAAP revenue of approximately $215 million to $217 million, demonstrating reported growth of 8% to 9%. For the full year 2022, the Company expects GAAP revenue of approximately $857 million to $859 million, demonstrating reported growth of 21% to 22%. Announcement • Oct 22
Novan, Inc., Epi Health and MC2 Therapeutics Present New Data in Multiple Posters Highlighting Wynzora’s Unique Pad Technology At the 42Nd Annual Fall Clinical Dermatology Conference Novan Inc. EPI Health and MC2 Therapeutics announced positive data demonstrating the impact of PAD Technology™ in WYNZORA® Cream in three posters featured at the 42nd Annual Fall Clinical Dermatology Conference® taking place October 20-23, 2022, in Las Vegas, NV. PAD Technology™, as explained in one of the posters, is a proprietary topical formulation and drug delivery system that allows CAL and BDP to co-exist in an aqueous environment (WYNZORA® Cream), for the first time.1 These active ingredients are stable at different pH levels, and without the unique properties of PAD Technology™ could not co-exist in a water-based formulation. In a second poster, diffusion of these active ingredients through human epidermis was investigated in an in vitro Franz diffusion study. This demonstrated that consistently higher amounts of CAL and BDP diffused through the epidermis with the PAD Technology™ based cream compared with the CAL/BDP topical suspension. The results were statistically significant in favor of CAL/BDP cream vs. CAL/BDP topical suspension (p<0.05) at all time points for both actives. Finally, WYNZORA® cream was compared to CAL/BDP topical suspension in a deposition study in 10 healthy human volunteers using tape strips taken at 1, 2, 4 and 8 hours. The results showed that more BDP was delivered to the stratum corneum and epidermis with the PAD Technology™-driven cream formulation than with the CAL/BDP topical suspension at every time point. EPI Health, a Novan company, and MC2 Therapeutics jointly market MC2 Therapeutics' WYNZORA® (calcipotriene and betamethasone dipropionate) Cream in the US, a once-daily aqueous cream that combines the benefits of a high potency steroid plus Vitamin D for the treatment of plaque psoriasis. WYNZORA® Cream demonstrates a rapid onset of action with results seen in efficacy, scale and itch as early as 1 week and continued improvement at 8 weeks.2,3 Under a Promotion and Collaboration Agreement between EPI Health and MC2 Therapeutics, EPI Health has exclusive detailing and distribution rights and the right to jointly with MC2 Therapeutics engage in promotional, regulatory and certain commercialization activities for WYNZORA® Cream in the United States. Announcement • Oct 11
Novanta Inc. to Report Q3, 2022 Results on Nov 08, 2022 Novanta Inc. announced that they will report Q3, 2022 results on Nov 08, 2022 Reported Earnings • Aug 10
Second quarter 2022 earnings released: EPS: US$0.49 (vs US$0.33 in 2Q 2021) Second quarter 2022 results: EPS: US$0.49 (up from US$0.33 in 2Q 2021). Revenue: US$215.4m (up 29% from 2Q 2021). Net income: US$17.5m (up 50% from 2Q 2021). Profit margin: 8.1% (up from 7.0% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 11%, compared to a 21% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Aug 10
Novanta Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2022 Novanta Inc. provided earnings guidance for the third quarter and full year 2022. For the quarter, the company expects GAAP revenue of approximately $214 million to $216 million, demonstrating reported growth of 20% to 22%.For the year, the company expects GAAP revenue of approximately $848 million to $852 million, demonstrating reported growth of 20% to 21%. Board Change • Aug 01
High number of new directors There are 6 new directors who have joined the board in the last 3 years. Director Barbara Hulit was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Announcement • Jul 28
Novanta Inc. Announces Director Changes On July 26, 2022, Ira J. Lamel resigned as a director of Novanta Inc. effective immediately. On July 26, 2022, the Board of Directors of the Company elected Barbara B. Hulit to the Board to fill an existing vacancy, effective July 26, 2022. Ms. Hulit will also serve as a member of the Environmental, Social and Governance Committee of the Board. Board Change • Jul 02
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Director Darlene J. Solomon was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Announcement • Jun 29
Novanta Inc. Announces Directorate Changes Novanta Inc. announced that on June 28, 2022, Brian King resigned as a director of the company, effective immediately. On June 28, 2022, the Board of Directors of the Company elected Darlene J. S. Solomon, Ph.D., to the Board to fill an existing vacancy, effective June 28, 2022. Ms. Solomon will also serve as a member of the Compensation Committee of the Board. Announcement • May 12
Novanta Inc. Provides Earnings Guidance for the Second Quarter of 2022 Novanta Inc. provided earnings guidance for the second quarter of 2022. The Company expects GAAP revenue of approximately $205 million to $213 million, demonstrating reported growth of 22% to 27%. Reported Earnings • May 11
First quarter 2022 earnings released: EPS: US$0.53 (vs US$0.32 in 1Q 2021) First quarter 2022 results: EPS: US$0.53 (up from US$0.32 in 1Q 2021). Revenue: US$204.2m (up 26% from 1Q 2021). Net income: US$18.8m (up 66% from 1Q 2021). Profit margin: 9.2% (up from 7.0% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 14%, compared to a 27% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 15% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Apr 12
Novanta Inc. to Report Q1, 2022 Results on May 10, 2022 Novanta Inc. announced that they will report Q1, 2022 results on May 10, 2022 Announcement • Mar 04
Novanta Inc., Annual General Meeting, May 12, 2022 Novanta Inc., Annual General Meeting, May 12, 2022. Reported Earnings • Mar 03
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Full year 2021 results: EPS: US$1.42 (up from US$1.27 in FY 2020). Revenue: US$706.8m (up 20% from FY 2020). Net income: US$50.3m (up 13% from FY 2020). Profit margin: 7.1% (down from 7.5% in FY 2020). Revenue exceeded analyst estimates by 1.0%. Over the next year, revenue is forecast to grow 17%, compared to a 23% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings. Announcement • Mar 03
Novanta Inc. Provides Revenue Guidance for the First Quarter and Full Year 2022 Novanta Inc. provided revenue guidance for the first quarter and full year 2022. For the quarter, the Company expects GAAP revenue to be in the range of approximately $192 million to $200 million. For the full year 2022, the Company expects GAAP revenue to be in the range of approximately $825 million to $845 million. Reported Earnings • Nov 11
Third quarter 2021 earnings released: EPS US$0.38 (vs US$0.23 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: US$177.7m (up 24% from 3Q 2020). Net income: US$13.6m (up 65% from 3Q 2020). Profit margin: 7.7% (up from 5.8% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 33% per year, which means it is well ahead of earnings. Reported Earnings • Aug 11
Second quarter 2021 earnings released: EPS US$0.33 (vs US$0.33 in 2Q 2020) The company reported a mediocre second quarter result with weaker profit margins, although earnings were flat and revenues improved. Second quarter 2021 results: Revenue: US$167.5m (up 16% from 2Q 2020). Net income: US$11.7m (flat on 2Q 2020). Profit margin: 7.0% (down from 8.1% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Jul 20
Novanta Inc. (NasdaqGS:NOVT) entered into an agreement to acquire ATI Industrial Automation, Inc. for approximately $170 million. Novanta Inc. (NasdaqGS:NOVT) entered into an agreement to acquire ATI Industrial Automation, Inc. for approximately $170 million on July 19, 2021. The consideration of $172 million will be paid upfront in cash and additional contingent cash payments associated with 2021 financial performance.
The acquisition will be financed using available cash and Novanta's revolving credit facility. ATI's expected 2021 revenue will be greater than $70 million on a full year basis. ATI's actual revenue and profit contribution to Novanta's 2021 financial results will depend on the ultimate date of the closing of the transaction, among other factors. The transaction is subject to customary closing conditions, including regulatory approvals and termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The transaction is expected to close in the third quarter of 2021. The acquisition is expected to be accretive to Novanta's free cash flow and non-GAAP earnings per share on a full year basis. John Arendale, Jeff Perkins, Brandt Carr, Jenson Dunn and Caroline Inglesby of Harris Williams LLC acted as financial advisor to ATI Industrial Automation. Reported Earnings • May 13
First quarter 2021 earnings released: EPS US$0.32 (vs US$0.34 in 1Q 2020) The company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2021 results: Revenue: US$162.6m (up 4.6% from 1Q 2020). Net income: US$11.3m (down 5.3% from 1Q 2020). Profit margin: 7.0% (down from 7.7% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth. Announcement • May 12
Novanta Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2021 Novanta Inc. provided earnings guidance for the second quarter and full year 2021. For the second quarter of 2021, the Company expects GAAP revenue of approximately $162 million to $165 million.
For the full year 2021, the Company expects GAAP revenue of approximately $645 million to $655 million. Reported Earnings • Mar 03
Full year 2020 earnings released: EPS US$1.27 (vs US$1.16 in FY 2019) The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: US$590.6m (down 5.7% from FY 2019). Net income: US$44.5m (up 9.2% from FY 2019). Profit margin: 7.5% (up from 6.5% in FY 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 36% per year, which means it is tracking significantly ahead of earnings growth. Analyst Estimate Surprise Post Earnings • Mar 03
Revenue beats expectations Revenue exceeded analyst estimates by 0.08%. Over the next year, revenue is forecast to grow 8.7%, compared to a 17% growth forecast for the Electronic industry in Germany. Announcement • Feb 27
Novanta Inc., Annual General Meeting, May 13, 2021 Novanta Inc., Annual General Meeting, May 13, 2021. Is New 90 Day High Low • Feb 13
New 90-day high: €117 The company is up 22% from its price of €96.00 on 13 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Electronic industry, which is up 18% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €34.81 per share. Announcement • Feb 03
Novanta Inc. to Report Q4, 2020 Results on Mar 01, 2021 Novanta Inc. announced that they will report Q4, 2020 results on Mar 01, 2021 Is New 90 Day High Low • Jan 26
New 90-day high: €110 The company is up 15% from its price of €95.50 on 28 October 2020. The German market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 24% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €36.26 per share. Is New 90 Day High Low • Jan 09
New 90-day high: €105 The company is up 9.0% from its price of €96.50 on 09 October 2020. The German market is also up 9.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it underperformed the Electronic industry, which is up 14% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €34.77 per share. Announcement • Dec 23
Novan, Inc. Enters into a Master Services Agreement (MSA) with Catalent Novan, Inc. announced it has entered into a Master Services Agreement (MSA) with Catalent, which will include support of chemistry, manufacturing and control (CMC) activities and development of an intranasal formulation of berdazimer sodium for use in the Company’s coronavirus (COVID-19) program. Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. Catalent’s advanced formulation development and manufacturing spans a range of technologies, along with integrated downstream clinical development and commercial supply solutions. Novan initiated in vitro assessments of its NITRICIL™ platform against the novel SARS-CoV-2 coronavirus, targeting the reduction of viral burden in differentiated normal human bronchial epithelial cells. The studies were conducted at the Institute for Antiviral Research at Utah State University, and these results demonstrated the first instance of an antiviral effect from a nitric oxide-based medicine in a 3-D tissue model that has similar structure to the human airway epithelium. The results from the in vitro assessment of concentrations as low as 0.75 mg/mL demonstrated that berdazimer sodium reduced 90% of virus after repeat dosing, once daily. Based on the scientific literature and data available to-date with berdazimer sodium and Novan’s product candidate SB206, Novan believes that nitric oxide may inhibit viral replication by disrupting protein function critical for viral replication and infection through generation of reactive intermediates. Following the completion of preclinical studies, Novan is targeting filing a potential IND application with the U.S. Food and Drug Administration and, subject to obtaining additional funding, targets initiating human clinical trials in the second half of 2021. Announcement • Dec 13
Novanta Inc. Elects Katherine A. Owen to the Board, Effective February 24, 2021 On December 8, 2020, the Board of Directors of Novanta Inc. elected Katherine A. Owen to the Board, effective February 24, 2021, to fill an existing vacancy on the Board. Analyst Estimate Surprise Post Earnings • Nov 11
Revenue beats expectations Revenue exceeded analyst estimates by 1.1%. Over the next year, revenue is forecast to grow 4.2%, compared to a 24% growth forecast for the Electronic industry in Germany. Reported Earnings • Nov 11
Third quarter 2020 earnings released: EPS US$0.23 The company reported a poor third quarter result with weaker earnings and revenues, although profit margins were flat. Third quarter 2020 results: Revenue: US$142.9m (down 7.2% from 3Q 2019). Net income: US$8.26m (down 7.5% from 3Q 2019). Profit margin: 5.8% (in line with 3Q 2019). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth. Is New 90 Day High Low • Nov 07
New 90-day high: €100.00 The company is up 4.0% from its price of €96.50 on 07 August 2020. The German market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Electronic industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €35.48 per share. Announcement • Oct 15
Novanta Inc. to Report Q3, 2020 Results on Nov 10, 2020 Novanta Inc. announced that they will report Q3, 2020 results at 11:59 AM, GMT Standard Time on Nov 10, 2020 Announcement • Aug 24
Novanta Inc. Not Able to Reliably Estimate the Future Impact on its Operations and Other Financial Results for the Full Year 2020 Novanta Inc. announced that due to the impact of the COVID-19 pandemic, the uncertain duration and scope of the pandemic, and the uncertain timing of the global public health and economic recovery, the Company is not able at this time to reliably estimate the future impact on its operations and other financial results for the full year 2020. Announcement • Jul 17
Novanta Inc. to Report Q2, 2020 Results on Aug 06, 2020 Novanta Inc. announced that they will report Q2, 2020 results at 11:59 AM, GMT Standard Time on Aug 06, 2020 Announcement • Jul 02
Novanta Inc.(NasdaqGS:NOVT) dropped from Russell 2000 Dynamic Index Novanta Inc.(NasdaqGS:NOVT) dropped from Russell 2000 Dynamic Index 
